Literature DB >> 2940209

In-vitro activity of ciprofloxacin, ceftriaxone and five other antimicrobial agents against 95 strains of Brucella melitensis.

J Bosch, J Liñares, M J López de Goicoechea, J Ariza, M C Cisnal, R Martin.   

Abstract

We studied the in-vitro activity of seven antibiotics against 95 strains of Brucella melitensis isolated in blood cultures of 95 patients with brucellosis. The minimum inhibitory concentration (MIC) was measured by the agar dilution method. All strains of B. melitensis were inhibited by doxycycline at 0.25 mg/l, tetracycline at 0.5 mg/l, ciprofloxacin at 0.5 mg/l, streptomycin at 1 mg/l, ceftriaxone at 1 mg/l, rifampicin at 4 mg/l and by co-trimoxazole at 0.5/9.5 mg/l. We did not find strains resistant to any of the antibiotics studied. All antibiotics, including ciprofloxacin and ceftriaxone, showed a good in-vitro activity against B. melitensis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2940209     DOI: 10.1093/jac/17.4.459

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  14 in total

1.  Lack of effective bactericidal activity of new quinolones against Brucella spp.

Authors:  J A García-Rodriguez; J E García Sánchez; I Trujillano
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

2.  Use of ciprofloxacin in the treatment of brucellosis.

Authors:  M Doğanay; B Aygen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-01       Impact factor: 3.267

Review 3.  Quinolones for treatment of human brucellosis: critical review of the evidence from microbiological and clinical studies.

Authors:  Matthew E Falagas; Ioannis A Bliziotis
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

4.  Efficacy of ciprofloxacin for treatment of Brucella melitensis infections.

Authors:  M B al-Sibai; M A Halim; M M el-Shaker; B A Khan; S M Qadri
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

5.  Possible implications of doxycycline-rifampin interaction for treatment of brucellosis.

Authors:  J D Colmenero; L C Fernández-Gallardo; J A Agúndez; J Sedeño; J Benítez; E Valverde
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

6.  Comparative in vitro activities of ofloxacin, difloxacin, ciprofloxacin, and other selected antimicrobial agents against Brucella melitensis.

Authors:  M Y Khan; M Dizon; F W Kiel
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

7.  In vitro activities of ceftriaxone and fusidic acid against 13 isolates of Coxiella burnetii, determined using the shell vial assay.

Authors:  H Torres; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

8.  In vitro susceptibility of Brucella melitensis to antibiotics.

Authors:  E Rubinstein; R Lang; B Shasha; B Hagar; L Diamanstein; G Joseph; M Anderson; K Harrison
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

9.  Relevance of in vitro antimicrobial susceptibility of Brucella melitensis to relapse rate in human brucellosis.

Authors:  J Ariza; J Bosch; F Gudiol; J Liñares; P F Viladrich; R Martín
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

Review 10.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.